A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Objective The long-acting glucagon-like peptide 1 receptor agonist liraglutide is linked to progressive and sustained weight loss in obese people with diabetes. However, its efficacy and safety in women with polycystic ovary syndrome (PCOS) has not yet been addressed.Design Thirty-two obese women (aged 27.6±7.2 years, BMI 39.5±6.2 kg/m(2)) with newly diagnosed PCOS were randomized to receive either liraglutide 1.2 mg QD sc (n=17) or metformin 1000 mg BID po (n=15) for 12 weeks; 28 patients completed the study (14 on liraglutide and 14 on metformin). The main outcome was change in body weight.Results Intention-to-treat analysis showed significant BMI (-0.98 kg/m(2); p<0.001), body weight (-2.52 kg; p<0.001), waist circumference (-3.38 cm; p<0.001) and whole-body fat mass (-1.26%; p<0.001) reduction in both treatment arms without significant differences between therapeutic groups. However, in a subgroup of patients (n=9) with insulin resistance (HOMA(IR) >2), severe obesity and higher odds ratio for the metabolic syndrome (OR=3.9), the patients fared much better with liraglutide than with metformin (mean BMI decreased 2.13 kg/m(2) vs. 0.62 kg/m(2), respectively).Conclusions Short-term liraglutide treatment was associated with significant weight loss in a subset of obese patients with newly diagnosed PCOS and a higher metabolic risk profile.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the same Authors in the second study, failed to demonstrate a reduction in HOMA-IR, fasting glucose and insulin and glucose and insulin during OGTT in both treated groups [58].”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [58]
In the citing paper
“the authors reported a significant reduction of total testosterone and LH in only metformin group, while treatment with liraglutide led to a significant LH increase, without differences in FG score between the two groups [58].”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [58]
In the citing paper
“However, in the subgroup of patients with insulin resistance, severe obesity and higher odds ratio for the metabolic syndrome, BMI decreased more with liraglutide than with metformin (2.13 kg/m2 vs. 0.62 kg/m2, respectively)”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [58]
In the citing paper
“Comparing the efficacy of liraglutide 1.2 mg/day vs metformin 1000 mg BID (twice daily), Jensterle et al. carried out two 12-week studies offering different results: the first study showed that liraglutide was superior to metformin in reducing body weight, BMI, and WC [57], while in the second study, both the treatments proved to be equally effective with no differences between the groups [58].”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [58]
In the citing paper
“suggesting a greater effect of liraglutide in subjects with insulin resistance and higher metabolic risk profile [58].”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [58]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Norman, R. J., Dewailly, D., Legro, R. S., & Hickey, T. E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61345-2 · Cited by 1,360
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Research works printed but not linked: 1
- American Diabetes Association, 2013 Standards of Medical Care in Diabetes-2013. Diabetes Care 36: Suppl 1: 26–27.
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Rosenfield, R. L., & Ehrmann, D. A. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1104 · Cited by 1,603
Sanchez-Garrido, M. A., & Tena-Sempere, M. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.01.001 · Cited by 557
Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics
Glueck, C. J., & Goldenberg, N. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.002 · Cited by 442
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists
Cena, H., Chiovato, L., & Nappi, R. E. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa285 · Cited by 356
“Contrary to these results, other studies with liraglutide in PCOS found unchanged bleeding frequency despite a decrease in body weight (89-96) and insulin resistance (88).”
BackgroundResultEffect of liraglutide on ectopic fat in polycystic ovary syndrome: Arandomized clinical trial
Frøssing, S., Nylander, M., Chabanova, E., Frystyk, J., Holst, J. J., Kistorp, C., Skouby, S. O., & Faber, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13053 · Cited by 178
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis
Han, Y., Li, Y., & He, B. (2019) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2019.04.017 · Cited by 159
Liu, X., Zhang, Y., Zheng, S., Lin, R., Xie, Y., Chen, H., Zheng, Y., Liu, E., Chen, L., Yan, J., et al. (2017) · Clinical Endocrinology · doi:10.1111/cen.13454 · Cited by 148
Bednarz, K., Kowalczyk, K., Cwynar, M., Czapla, D., Czarkowski, W., Kmita, D., Nowak, A., & Madej, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084334 · Cited by 148
Recent advances in the understanding and management of polycystic ovary syndrome
Rocha, A. L., Oliveira, F. R., Azevedo, R. C., Silva, V. A., Peres, T. M., Candido, A. L., Gomes, K. B., & Reis, F. M. (2019) · F1000Research · doi:10.12688/f1000research.15318.1 · Cited by 142
Nylander, M., Frøssing, S., Clausen, H. V., Kistorp, C., Faber, J., & Skouby, S. O. (2017) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2017.03.023 · Cited by 139
The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective
Jensterle, M., Janez, A., Fliers, E., DeVries, J. H., Vrtacnik-Bokal, E., & Siegelaar, S. E. (2019) · Human Reproduction Update · doi:10.1093/humupd/dmz019 · Cited by 128
Self-citationPsychopharmacological advances in eating disorders
Himmerich, H., & Treasure, J. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1383895 · Cited by 119
Liu, Y., Ruan, B., Jiang, H., Le, S., Liu, Y., Ao, X., Huang, Y., Shi, X., Xue, R., Fu, X., et al. (2023) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.04.017 · Cited by 110
Jensterle, M., Kravos, N. A., Goričar, K., & Janez, A. (2017) · BMC Endocrine Disorders · doi:10.1186/s12902-017-0155-9 · Cited by 93
“Addition of metformin resulting in higher proportion of subjects achieving clinically meaningful ≥ 5% weight reduction in almost 60% compared to about 40% of good responders in low dose liraglutide monotherapy arm [27].”
BackgroundSelf-citationWang, F., Wu, Y. T., Zhu, Y. ‐., Ding, T., Batterham, R. L., Qu, F., & Hardiman, P. (2018) · Obesity Reviews · doi:10.1111/obr.12720 · Cited by 99
“The high risk of allover bias originated from missing outcome data (31,37,45,50,51) and selection of the reported results (54).”
BackgroundMetabolic hormones are integral regulators of female reproductive health and function
Athar, F., Karmani, M., & Templeman, N. M. (2023) · Bioscience Reports · doi:10.1042/bsr20231916 · Cited by 91
GLP-1 receptor agonists in the treatment of polycystic ovary syndrome
Lamos, E. M., Malek, R., & Davis, S. N. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1292125 · Cited by 76
“2 mg daily in newly diagnosed women with PCOS [38].”
BackgroundInsulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS
Xing, C., Li, C., & He, B. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa337 · Cited by 69
“Jensterle et al (18, 19) found no significant FAI difference between metformin and liraglutide.”
BackgroundMethodInfluentialA systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries
Niafar, M., Pourafkari, L., Porhomayon, J., & Nader, N. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3976-7 · Cited by 66
Zhou, L., Qu, H., Yang, L., & Shou, L. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01500-5 · Cited by 66
Cardio-Metabolic Disease and Polycystic Ovarian Syndrome (PCOS): A Narrative Review
Sangaraju, S. L., Yepez, D., Grandes, X. A., Manjunatha, R. T., & Habib, S. (2022) · Cureus · doi:10.7759/cureus.25076 · Cited by 95
Cardiometabolic risk in polycystic ovary syndrome
Bajuk Studen, K., & Pfeifer, M. (2018) · Endocrine Connections · doi:10.1530/ec-18-0129 · Cited by 64
Self-citationGoldberg, A., Graca, S., Liu, J., Rao, V., Witchel, S. F., Pena, A., Li, R., Mousa, A., Tay, C. T., Pattuwage, L., et al. (2024) · Obesity Reviews · doi:10.1111/obr.13704 · Cited by 59
Guo, X., Zhou, Z., Lyu, X., Xu, H., Zhu, H., Pan, H., Wang, L., Yang, H., & Gong, F. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1844-1176 · Cited by 59
JENSTERLE, M., GORICAR, K., & JANEZ, A. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3081 · Cited by 56
“A small randomized study conducted on treatment naïve obese women with PCOS demonstrated no significant difference between metformin and low‑dose LIRA treatment following the measurement of patient obesity, metabolic and androgen profiles (11).”
InfluentialSelf-citationContribution of Macrophage Polarization to Metabolic Diseases
Komohara, Y., Fujiwara, Y., Ohnishi, K., Shiraishi, D., & Takeya, M. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.32359 · Cited by 55
Jensterle, M., Herman, R., & Janež, A. (2022) · Biomedicines · doi:10.3390/biomedicines10081989 · Cited by 50
“However, several additional studies with liraglutide in PCOS found unaltered menstrual rate despite reductions in body weight [20,21,29] and insulin resistance [28].”
BackgroundSelf-citationSanchez-Garrido, M. A., Serrano-López, V., Ruíz-Pino, F., Vazquez, M. J., Rodríguez-Martín, A., Torres, E., Velasco, I., Rodríguez, A., Chicano‐Gálvez, E., Mora-Ortiz, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52898-y · Cited by 60
Nylander, M., Frøssing, S., Kistorp, C., Faber, J., & Skouby, S. O. (2017) · Endocrine Connections · doi:10.1530/ec-16-0113 · Cited by 44
Targets to treat metabolic syndrome in polycystic ovary syndrome
Mahalingaiah, S., & Diamanti‐Kandarakis, E. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1101067 · Cited by 48
“[139] Two studies do suggest a potential benefit for vitamin D evaluation and treatment in PCOS-MBS,[140,141] but further research is needed regarding the utility of vitamin D supplementation or treatment in women with PCOS-MBS.”
BackgroundInfluentialShao, S., Zhang, X., Xu, Q., Pan, R., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108270 · Cited by 46
Papaetis, G. S., & Kyriacou, A. (2022) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/151695 · Cited by 57
Vine, D., Wang, Y., Jetha, M., Ball, G., & Proctor, S. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2854 · Cited by 40
Zheng, S., Zhang, Y., Long, T., Lu, J., Liu, X., Yan, J., Chen, L., Gong, Y., & Wang, F. (2017) · Obesity Medicine · doi:10.1016/j.obmed.2017.06.003 · Cited by 45
Ge, J. J., Wang, D., Song, W., Shen, S., & Ge, W. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01666-6 · Cited by 47
Ferjan, S., Janez, A., & Jensterle, M. (2017) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2017.0095 · Cited by 36
Self-citationCurrent and emerging drug treatment strategies for polycystic ovary syndrome
Helvaci, N., & Yildiz, B. O. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2108702 · Cited by 35
Ma, R., Ding, X., Wang, Y., Deng, Y., & Sun, A. (2021) · Medicine · doi:10.1097/md.0000000000026295 · Cited by 34
Current and future aspects of several adjunctive treatment strategies in polycystic ovary syndrome
Banaszewska, B., Pawelczyk, L. A., & Spaczyński, R. (2019) · Reproductive Biology · doi:10.1016/j.repbio.2019.09.006 · Cited by 42
Lyu, X., Lyu, T., Wang, X., Zhu, H., Pan, H., Wang, L., Yang, H., & Gong, F. (2021) · International Journal of Endocrinology · doi:10.1155/2021/6616693 · Cited by 41
“[28] Some concerns Some concerns Low risk Low risk Low risk Some concerns Jensterle et al.”
BackgroundLin, S., Deng, Y., Huang, J., Li, M., Sooranna, S. R., Qin, M., & Tan, B. (2025) · Scientific Reports · doi:10.1038/s41598-025-99622-4 · Cited by 35
Zheng, S., Liu, E., Zhang, Y., Long, T., Liu, X., Gong, Y., Mai, T., Shen, H., Chen, H., Lin, R., et al. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej18-0153 · Cited by 35
Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?
Pugliese, G., de Alteriis, G., Muscogiuri, G., Barrea, L., Verde, L., Zumbolo, F., Colao, A., & Savastano, S. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02084-6 · Cited by 29
Non-Hormonal Treatment Options for Regulation of Menstrual Cycle in Adolescents with PCOS
Reiser, E., Lanbach, J., Böttcher, B., & Tóth, B. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010067 · Cited by 41
“Another study, also conducted over 12 weeks, showed similar results as no significant changes in menstrual frequency between metformin and liraglutide treatment were found [55].”
ResultLiraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome
Papaetis, G. S., Filippou, P. K., Constantinidou, K. G., & Stylianou, C. S. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00942-2 · Cited by 25
Bader, S., Bhatti, R., Mussa, B. M., & Abusanana, S. (2024) · Women s Health · doi:10.1177/17455057241234530 · Cited by 46
Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review
Batsis, J. A., Gavras, A., Gross, D. C., Cheever, C. R., da Silva, B. R., Filho, L. F. M., Jones, E. P., Batchek, D. J., Khandpekar, S. G., Patel, R., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-00478 · Cited by 34
Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity
Yazıcı, D., Eser, H. Y., Kiyici, S. K., Sancak, S., Sezer, H., Uygur, M., & Yumuk, V. (2022) · Obesity Facts · doi:10.1159/000526808 · Cited by 29
Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS, a narrative review
Monney, M., Mavromati, M., Leboulleux, S., & Gariani, K. (2025) · Endocrine Connections · doi:10.1530/ec-24-0529 · Cited by 30
“…on fasting glucose, insulin sensitivity (homeostatic model assessment for insulin resistance – HOMA-IR), metabolic syndrome and hormonal markers (testosterone, androstenedione and SHBG), but some studies were unable to demonstrate clinical endocrine bene fi ts (menstrual frequency) (54, 56, 57).”
Novel Antidiabetic Medications in Polycystic Ovary Syndrome
Somagutta, M. K. R., Jain, M. S., Uday, U., Pendyala, S. K., Mahadevaiah, A., Mahmutaj, G., Jarapala, N., Gad, M. A., Srinivas, P. M., Sasidharan, N., et al. (2022) · Discoveries · doi:10.15190/d.2022.4 · Cited by 22
Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes
Ortiz-Flores, A. E., Luque‐Ramírez, M., & Escobar-Morreale, H. F. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1528231 · Cited by 23
“Liraglutide and exenatide have been also compared with metformin in PCOS patients [98,99].”
BackgroundResultSridharan, K., & Sivaramakrishnan, G. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01730-8 · Cited by 24
Samarasinghe, S., Oštarijaš, E., Long, M. J., Erridge, S., Purkayastha, S., Dimitriadis, G. K., & Miras, A. D. (2024) · Obesity Reviews · doi:10.1111/obr.13744 · Cited by 20
“Trials of GLP-1 RA therapy in women with PCOS and obesity showed that both liraglutide and exenatide are effective in weight reduction either as monotherapy or in combination with metformin, 45,50,51 which is in keeping with our results.”
ResultNon-insulin pharmacological therapies for treating type 1 diabetes
Frandsen, C. S., Dejgaard, T. F., Madsbad, S., & Holst, J. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1483339 · Cited by 18
“Moreover, the addition of liraglutide to basal/bolus insulin therapy in overweight/obese individuals with T1D has been shown to significantly improve anthropometric and metabolic profiles [53], which is consistent with data from patients with T2D (LEAD-2 trial) [54] and from women with polycystic ovary syndrome treate…”
ResultWhat is new in the landscape of insulin-sensitizing agents for polycystic ovary syndrome treatment
Romualdi, D., Versace, V., & Lanzone, A. (2020) · Therapeutic Advances in Reproductive Health · doi:10.1177/2633494120908709 · Cited by 20
Sawicka‐Gutaj, N., Gruszczyński, D., Nijakowski, K., Derwich-Rudowicz, A., Krenz, M., Kumar, A. A., Lu, P.-Y., & Ruchała, M. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02088-1 · Cited by 24
“Despite attempts to minimize bias through a systematic and comprehensive search strategy, unpublished or negative studies may have been overlooked.”
Tian, D., Chen, W., Xu, Q., Li, X., & Lv, Q. (2022) · Minerva Medica · doi:10.23736/s0026-4806.21.07085-3 · Cited by 17
Bo, Y., Zhao, J., Liu, C., & Yu, T. (2025) · BMC Women s Health · doi:10.1186/s12905-025-03594-6 · Cited by 20
Babazadeh, D., Wyatt, S., & Steinberg, F. M. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100491 · Cited by 16
“%) focused solely on liraglutide [43, 46 – 98].”
Alalami, H., Sathyapalan, T., & Atkin, S. L. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818805674 · Cited by 12
An Overview on the Assessment and Management of Polycystic Ovarian Syndrome
Alhazmi, R. A., Khayat, S. K., Albakri, M. H., Alruwaili, W. S., Bayazed, H. A., Almubarak, S. A., Albahrani, A. A., Alshahrani, A. A., Alharkan, A. A., & Alreqei, H. M. (2022) · World Journal of Environmental Biosciences · doi:10.51847/yaaa2745zy · Cited by 11
“Liraglutide was found to be helpful in causing considerable weight loss and reducing waist circumference in obese women with PCOS (Jensterle et al. , 2015).”
Popovic, M., Monnerat, S., TAYLOR, A. E. R., Gilligan, L. C., Schiffer, L., Arlt, W., Vogt, D., Geyter, C. D., Hutter, N., Donath, M. Y., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1435698 · Cited by 12
Çelik, Ö., Yazıcı, D., Ciudin, A., Macut, D., Micić, D., Yumuk, V., & Yıldız, B. O. (2025) · Obesity Facts · doi:10.1159/000547055 · Cited by 14
“Jensterle et al. [53] found LIRA 3 mg to be more effective than low-dose LIRA (1.2 mg) plus MET in decreasing BMI and WC. Additionally, combination therapy further improved androgen profiles and was better tolerated.”
InfluentialSrinivasan, D., & Lofton, H. F. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100016 · Cited by 12
Tong, X., Song, X., Zhang, Y., & Zhao, Q. (2024) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2024.2380422 · Cited by 13
“2014, Jensterle et al .”
Liraglutide (Saxenda®) as a Treatment for Obesity
Onge, E. S., Miller, S. A., & Motycka, C. A. (2016) · Food and Nutrition Sciences · doi:10.4236/fns.2016.74024 · Cited by 15
“The efficacy of liraglutide was evaluated in another trial of 84 overweight or obese women who had a diagnosis of PCOS [28].”
BackgroundMerhi, Z. O., Karekar, M., & Mouanness, M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0326210 · Cited by 8
The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome
Chatzis, P., Τζιόμαλος, Κ., Pratilas, G. C., Makris, V., Sotiriadis, A., & Dinas, K. D. (2018) · Folia Medica · doi:10.2478/folmed-2018-0036 · Cited by 8
The Interaction of Obesity and Reproductive Function in Adolescents
Elliott, V., Waldrop, S., Wiromrat, P., Carreau, A., & Cree‐Green, M. (2022) · Seminars in Reproductive Medicine · doi:10.1055/s-0042-1744495 · Cited by 8
Wang, J., Li, L., Zhou, J., Pan, X., Qi, Q., Sun, H., & Wang, L. (2024) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2024.01003 · Cited by 7
Su, L., Hao, X., & Lu, W. (2025) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2025.j009 · Cited by 6
Rao, M., Zumbro, E. L., Broughton, K. S., & LeMieux, M. J. (2021) · Nutrition Research · doi:10.1016/j.nutres.2021.06.005 · Cited by 5
RetractedAbdalla, M. A., Shah, N. Z., Deshmukh, H., Sahebkar, A., Östlundh, L., Al‐Rifai, R. H., Atkin, S. L., & Sathyapalan, T. (2022) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-022-06549-6 · Cited by 6
Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome
Kourtidou, C., & Τζιόμαλος, Κ. (2023) · Biomedicines · doi:10.3390/biomedicines11020496 · Cited by 7
Abdalla, M. A., Shah, N. Z., Deshmukh, H., Sahebkar, A., Östlundh, L., Al‐Rifai, R. H., Atkin, S. L., & Sathyapalan, T. (2021) · Clinical Endocrinology · doi:10.1111/cen.14663 · Cited by 5
“5%) evaluated liraglutide compared with metformin.(69,86) Five RCTs (6.”
BackgroundInfluentialIncretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map
Jensterle, M., & Janež, A. (2026) · Drugs · doi:10.1007/s40265-026-02325-x · Cited by 5
“No major endocrine changes were observed [18].”
InfluentialSelf-citationAkel, M., Ziq, A., Kaldas, P., Hamden, J., Omari, A. R., & Silanee, A. (2024) · Cureus · doi:10.7759/cureus.73687 · Cited by 5
Polycystic ovary syndrome and obesity: a modern paradigm
Khamoshina, M. B., Artemenko, Y. S., Bayramova, A. A., Андреевна, Р. В., & Orazov, M. R. (2022) · RUDN Journal of Medicine · doi:10.22363/2313-0245-2022-26-4-382-395 · Cited by 5
Fernandes, A., Gordon, A., & Sweeting, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70116 · Cited by 3
Vardhan, S., Arnott, C. G., Chen, A., Frolova, A. I., Meka, R. A., Raghuraman, N., Vijay, A., Yoo, S. G., & Mahmoud, Z. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101471 · Cited by 4
Almubaddil, K. H., Alotaibi, M., Mutreb, L. B., Alanazi, F., & Altulihee, M. A. (2026) · Cureus · doi:10.7759/cureus.103927 · Cited by 6
Glucagon-like peptide-1 agonists for weight loss in people with obesity
Kirk, S., Shamliyan, T., & Middleton, M. (2017) · Obesity Medicine · doi:10.1016/j.obmed.2017.01.003 · Cited by 2
Liraglutide for the treatment of obesity
Bronkhorst, E., & Schellack, N. (2016) · South African Family Practice · doi:10.4102/safp.v58i3.4496 · Cited by 2
Lin, J., Yang, R., Zhuang, J., Zhang, W., Tong, Q., Liu, J., Kang, Y., & Yuan, Y. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-026-02078-x · Cited by 3
Buragohain, S., Sarma, I. D., Saikia, D., Malakar, H., Das, B. K., Khound, M., & Lahon, J. (2026) · Cureus · doi:10.7759/cureus.106751 · Cited by 5
“Jensterle et al. reported that liraglutide monotherapy was superior to metformin for BMI reduction in a pilot trial [13], with a 12-week course producing clinically meaningful reductions in newly diagnosed PCOS [14].”
Omarion, A., Ayasa, Y., Omarion, Z., Jayouse, B., & Ayesh, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1833904 · Cited by 2
A polycystás ovarium szindróma tüneteinek bizonyítékokon alapuló terápiája
Gődény, S., & Csenteri, O. K. (2015) · Orvosi Hetilap · doi:10.1556/650.2015.30253 · Cited by 1
“PCOS-ben történő alkalmazása főleg a nagyobb metabolikus kockázattal járó fenotípusnál lehet előnyös [23].”
Glucagon-like peptide 1 agonists: a ray of hope for the treatment of polycystic ovarian syndrome
Babar, A., Ali, R., & Zuhair, V. (2023) · Journal of the Pakistan Medical Association · doi:10.47391/jpma.9666 · Cited by 1
Potential New Pharmacological Approaches in Obese Women with Polycystic Ovary Syndrome
Janež, A., & Jensterle, M. (2017) · Journal of Diabetes and Obesity · doi:10.15436/2376-0494.17.1246 · Cited by 2
“Furthermore, short-term treatment with liraglutide was associated with significantly greater weight loss in a subset of obese patients with newly diagnosed PCOS and higher metabolic risk profile when compared to metformin and lifestyle intervention[14].”
BackgroundSelf-citationIncretin System: New Pharmacological Target in Obese Women with Polycystic Ovary Syndrome
Sever, M. J., Ferjan, S., & Janež, A. (2018) · InTech eBooks · doi:10.5772/intechopen.70648 · Cited by 1
“Another study with newly diagnosed obese PCOS patients with high metabolic risk also showed significantly greater weight reduction with liraglutide therapy when compared to metformin and lifestyle intervention [54].”
ResultLi, L., Wang, S., Du, M.-R., & Jiang, S. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001418 · Cited by 1
“The exclusion criteria included (1) non-RCTs; (2) duplicate publications; (3) theses, conference papers, or reviews; and (4) publication of abstract alone.”
BackgroundMethodInfluentialAzarias, W. S., & Sinésio, L. E. M. (2021) · Editora Conhecimento Livre eBooks · doi:10.37423/211004820 · Cited by 1
Pregnancy Complications & Management Related to Polycystic Ovarian Syndrome: An Overview
Davande, C. C., Gade, A. R., & Kanekar, A. S. (2021) · Cited by 1
PREVENÇAO DO CANCER CERVICO UTERINO; FATORES PARA NAO REALIZAÇAO
Magalhães, A. W. D., & MEDEIROS, A. A. D. A. (2021) · Editora Conhecimento Livre eBooks · doi:10.37423/211004933
A INFLUÊNCIA DA LIRAGLUTIDA NOS RECEPTOR GLP-1 DURANTE O PROCESSO DE EMAGRECIMENTO
de Carvalho, R. A., Neto, V. F., Siqueira, R. D. M., de Carvalho, P. S. V., de Carvalho, C. S. V., Fróes, Y. N., Pavão, F. M. F. A., Filho, J. J. J. P., da Silva, D. F., & Silva, M. R. C. (2021) · Editora Conhecimento Livre eBooks · doi:10.37423/211004889
Armelin, P. V. D. A. (2021) · Editora Conhecimento Livre eBooks · doi:10.37423/211004898
VIVÊNCIA DE IDOSOS EM INSTITUIÇÃO DE LONGA PERMANÊNCIA EM JOÃO PESSOA - PB: RELATO DE EXPERIÊNCIA
Carvalho, M. D. S., Barbosa, L. C. D. C., Aranda, L. D., & de Holanda, V. M. V. M. (2021) · Editora Conhecimento Livre eBooks · doi:10.37423/211004928
Silva, A. C. D. O., de Carvalho, R. R., & Marques, A. (2021) · Editora Conhecimento Livre eBooks · doi:10.37423/211104956
AVALIAÇÃO DA COBERTURA VACINAL DE CRIANÇAS MENORES DE 5 ANOS NO HAITI - 2016-2018
Bayard, C., Lexius, O., Ribeiro, M. D. N. D. S., dos Santos, E. R., & Melo, G. Z. D. S. (2021) · Editora Conhecimento Livre eBooks · doi:10.37423/211004852
Metadata
- Authors
- Jensterle, M., Kravos, N. A., Pfeifer, M., Kocjan, T., & Janez, A.
- Affiliations
- Ljubljana University Medical Centre (SI)
- Venue
- Hormones
- Published
- 2015-01
- Volume
- 14
- Issue
- 1
- Pages
- 81-90
- ISSN
- 1109-3099 (ISSN-L)
- 2520-8721
- OpenAlex
- W2330618995
- Cited by
- 117
- References
- 39
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 10 · 2023: 8 · 2022: 18 · 2021: 17 · 2020: 5 · 2019: 5 · 2018: 8 · 2017: 11 · 2016: 6 · 2015: 4
- FWCI
- 11.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- HORMONES (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- liraglutide, polycystic ovary syndrome, obesity, weight loss, GLP-1 receptor agonists, metformin, insulin resistance, metabolic syndrome, body mass index, waist circumference, fat mass
- MeSH terms
- Liraglutide, Adult, Blood Glucose, Body Weight, Female, Humans, Hypoglycemic Agents, Metformin, Obesity, Polycystic Ovary Syndrome, Weight Loss, Body Mass Index, Treatment Outcome, Incretins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.